Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 4/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 6/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | TDP2 | O95551 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.36 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17758356 | 0.84 | ALDH1A1 (0.43) | PDE3BPDE3ANOTUMKMT2AGRIA1 | |
| SCHEMBL17758352 | 0.78 | PDE3B (0.53) | PDE3BPDE3APARP1MAP4K4KMT2A | |
| SCHEMBL2422734 | 0.75 | PDE3B (0.45) | PDE3BPDE3ANOTUMTDP2 | |
| SCHEMBL17758329 | 0.73 | GRIA1 (0.44) | PDE3BPDE3ANOTUMKMT2AGRIA1 | |
| SCHEMBL2417276 | 0.72 | KMT2A (0.55) | KIF11KMT2A | |
| SCHEMBL30443527 | 0.72 | KMT2A (0.55) | KIF11KMT2A | |
| SCHEMBL8354646 | 0.70 | MAPK14 (0.53) | PARP1KIF11NOTUM | |
| SCHEMBL1578151 | 0.69 | KIF11 (0.61) | KIF11MAP4K4 | |
| SCHEMBL6011433 | 0.69 | KIF11 (0.61) | KIF11MAP4K4 | |
| SCHEMBL16652113 | 0.69 | ALDH1A1 (0.61) | PARP1KIF11NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160136077-A1 | OXIDATION DYEING PROCESS USING A COMPOSITION COMPRISING AN AMINOBENZIMIDAZOLONE OXIDATION BASE AND A METAL CATALYST | L'OREAL (FR) | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160136077-A1 | OXIDATION DYEING PROCESS USING A COMPOSITION COMPRISING AN AMINOBENZIMIDAZOLONE OXIDATION BASE AND A METAL CATALYST | KRT18, CYB5R3, AOC3 | PDE3B 4166/4885PDE3A 4129/4885PARP1 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.